logo
logo
Sign in

Pharmacogenomics explores how the genome affects drug responses.

avatar
Shivani
Pharmacogenomics explores how the genome affects drug responses.

Pythagoras, circa 510 BC, was the first to recognise pharmacogenomics when he linked the hazards of fava bean consumption to hemolytic anaemia and oxidative stress. In the 1950s, this identification was confirmed and linked to a G6PD deficit, which was dubbed favism. Although the first official publication was in 1961, the unofficial origins of this science were in the 1950s. In 1956, the first reports of protracted paralysis and deadly reactions connected to genetic variations in patients lacking butyryl-cholinesterase ('pseudocholinesterase') after succinylcholine injection during anaesthesia were published.


Friedrich Vogel of Heidelberg, Germany invented the term pharmacogenetic in 1959. (although some papers suggest it was 1957 or 1958). The inference of genetic involvement in drug metabolism was supported by twin studies in the late 1960s, with identical twins showing striking similarities in drug reaction when compared to fraternal twins. Around the 1990s, the term pharmacogenomics became popular.


Read more @ https://tradove.com/blog/What-is-pharmacogenomics.html


collect
0
avatar
Shivani
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more